Market Capitalization (Millions $) |
57 |
Shares
Outstanding (Millions) |
49 |
Employees |
99 |
Revenues (TTM) (Millions $) |
9 |
Net Income (TTM) (Millions $) |
-36 |
Cash Flow (TTM) (Millions $) |
-15 |
Capital Exp. (TTM) (Millions $) |
0 |
Scynexis Inc
Scynexis Inc is a biotechnology company that focuses on developing and commercializing highly innovative therapies to address serious and life-threatening fungal infections. Founded in 2000 and headquartered in Jersey City, New Jersey, USA, Scynexis has an experienced leadership team that is dedicated to advancing medical science and improving the lives of patients worldwide.
Scynexis develops therapies for a wide range of fungal infections, including Candida and Aspergillosis, which are often associated with high morbidity and mortality rates. Their lead product candidate, ibrexafungerp (formerly SCY-078), is a novel antifungal drug that acts by inhibiting the fungal enzyme glucan synthase, which is required for the production of fungal cell walls. Ibrexafungerp has demonstrated that it can provide broad-spectrum activity against a range of fungal species and is expected to have a lower risk of developing drug resistance when compared to other available antifungal agents.
In addition to its lead product candidate, Scynexis has an extensive pipeline of antifungal products in development. They are exploring the potential of using ibrexafungerp to target other types of fungal infections, including those caused by drug-resistant strains. Also, Scynexis has developed a proprietary platform technology for the discovery and development of novel antifungal compounds, which they believe can significantly advance the treatment of severe fungal infections.
Scynexis has been successful in raising significant amounts of capital, enabling it to fund its operations and research activities. Moreover, they have established partnerships with reputable organizations, such as the National Institutes of Health (NIH), to advance their research and develop breakthrough treatments. Their partnerships also extend to commercialization deals with established pharmaceutical companies, such as Jiangsu Hengrui Medicine Co., Ltd. and IMMY Inc.
Overall, Scynexis is a pioneering biotechnology company that is dedicated to advancing the field of antifungal therapy. They aim to provide innovative, effective treatments to patients suffering from serious fungal infections and improve overall patient outcomes. Their commitment to scientific excellence and partnership collaborations make them a leader in the field of antifungal research and development.
Company Address: 1 Evertrust Plaza Jersey City 7302 NJ
Company Phone Number: 884-5485 Stock Exchange / Ticker: NASDAQ SCYX
|